Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination.
Yasemin GoereciNina N KleinebergMarie MadlenerHannah NeuschmeltingGereon R FinkClemens WarnkeHenning StetefeldPublished in: Neurological research and practice (2021)
The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection with SARS-CoV-2 has been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily leading to venous thromboses. Here, we report two cases of major arterial occlusions after ChAdOx1 nCov-19 vaccination, comprising a 42-year-old woman with thrombotic occlusion of the left carotid artery, and a 62-year-old man with occlusion of distal aorta and iliac arteries. Both were successfully treated with intravenous immunoglobulins and non-heparin anticoagulant agents leading to a beneficial short-term outcome of 6 weeks in case 1 and four months in case 2.
Keyphrases
- sars cov
- venous thromboembolism
- respiratory syndrome coronavirus
- coronavirus disease
- high glucose
- atrial fibrillation
- diabetic rats
- high dose
- aortic valve
- minimally invasive
- pulmonary artery
- growth factor
- endothelial cells
- blood flow
- endovascular treatment
- gestational age
- pulmonary hypertension
- pulmonary arterial hypertension
- preterm birth
- stress induced